Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible

Biopharmaceutics and Drug Disposition

Volumn 32, Issue 5, 2011, Pages 261-275

  Reddy, Micaela B ^a   Connor, Alyson ^b   Brennan, Barbara J ^a   Morcos, Peter N ^a   Zhou, Amy ^a   McLawhon, Pamela ^a   Fretland, Adrian ^a   Evans, Philip ^b   Smith, Patrick ^a   Tran, Jonathan Q ^a,b  

^a Quotient Clinical ^*

^b BIOGEN   (United States)

Author keywords

absorption modeling; controlled release; danoprevir; Enterion ; hepatitis C

Indexed keywords

DANOPREVIR;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED RELEASE FORMULATION; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; FEASIBILITY STUDY; GASTROINTESTINAL TRACT; HAPLORHINI; HUMAN; HUMAN EXPERIMENT; MALE; MATHEMATICAL MODEL; NONHUMAN; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEASIBILITY STUDIES; HUMANS; INTESTINAL ABSORPTION; LACTAMS; MACACA FASCICULARIS; MALE; MODELS, BIOLOGICAL; SULFONAMIDES; YOUNG ADULT;

EID: 79959737239     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.756     Document Type: Article

References (34)

1. Seiwert SD, Andrews SW, Jiang Y, et al,. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 2008; 52: 4432-4441.
2. Forestier N, Larrey DG, Guyader D, et al,. Treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3/4A protease inhibitor ITMN-191 leads to rapid reductions in plasma HCV RNA: results of a phase 1b multiple ascending dose (MAD) study. Hepatology 2008; 48 (S1): 1132A.
3. Lo Re V 3rd, Amorosa VK, Localio AR, et al,. Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis 2009; 48: 186-193.
4. Stone VE, Hogan JW, Schuman P, et al,. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the HER study. J Acquir Immune Defic Syndr 2001; 28: 124-131. (Pubitemid 32971059)
5. Swindells S, Mohr J, Bester M, et al,. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30. (Pubitemid 30432540)
6. Rubino C, Bradford WZ, Forrest A, et al,. Pharmacokinetic-pharmacodynamic (PK-PD) relationships for ITMN-191 in a phase 1 multiple ascending dose trial in patients with genotype 1 chronic hepatitis C infection. Hepatology 2008; 48 (S1): 1140A-1141A.
7. Shargel L, Wu-Pong S, Yu ABC,. Applied Biopharmaceutics and Pharmacokinetics, 5th edn. McGraw Hill: New York, 2005; 892 pp.
8. Hardy JG, Wilson CG, Wood E,. Drug delivery to the proximal colon. J Pharm Pharmacol 1985; 37: 874-877. (Pubitemid 16222321)
9. Hardy JG, Healy JNC, Lee SW, et al,. Gastrointestinal transit of an enteric coated delayed release 5-aminosalicylic acid tablet. Aliment Pharmacol Ther 1987; 1: 209-216.
10. Connor A, King G, Jones K,. Evaluation of human regional bioavailability to assess whether modified release development is feasible. Proc AAPS 2007; 9 (S2): 724.
11. Takahashi M, Washio T, Suzuki N, et al,. The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans. J Pharm Sci 2009; 98: 4343-4353.
12. Nishimuta H, Sato K, Mizuki Y, et al,. Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys. Drug Metab Dispos 2010; 38: 1967-1975.
13. Agoram B, Woltosz WS, Bolger MB,. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001; 50 (Suppl. 1): S41-S67. (Pubitemid 32905355)
14. Parrott N, Lave T,. Prediction of intestinal absorption: comparative assessment of GASTROPLUS™ and IDEA™. Eur J Pharm Sci 2002; 17: 51-61. (Pubitemid 35287171)
15. Yu LX, Crison JR, Amidon, GL,. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm 1996; 140: 111-118. (Pubitemid 26276720)
16. Simulations Plus, Inc. GastroPlus™ User Manual for Version 6.1. November 2009. Lancaster, CA
17. Galia E, Nicolaides E, Horter D, et al,. Evaluation of various dissolution media for predicting in vivo performance of Class I and II drugs. Pharm Res 1998; 15: 698-705. (Pubitemid 28275645)
18. Hubatsch I, Ragnarsson EGE, Artursson P,. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc 2007; 2: 2111-2119. (Pubitemid 351565848)
19. Ungell A-L, Nylander, S, Bergstrand S, et al,. Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci 1998; 87: 360-366. (Pubitemid 28204591)
20. Kondo H, Watanabe T, Yokohama S, et al,. Effect of food on gastrointestinal transit of liquids in cynomolgus monkeys. Biopharm Drug Dispos 2003; 24: 141-151. (Pubitemid 36656387)
21. Willmann S, Edginton AN, Dressman JB,. Development and validation of a physiology-based model for the prediction of oral absorption in monkeys. Pharm Res 2007; 24: 1275-1282. (Pubitemid 46880982)
22. Fagerholm U, Johansson M, Lennernas H,. Comparison between permeability coefficients in rat and human jejunum. Pharm Res 1996; 13: 1336-1342. (Pubitemid 26344978)
23. Kim J-S, Mitchell S, Kijek P, et al,. The suitability of an in situ perfusion model for permeability determinations: Utility for BCS Class I biowaiver requests. Mol Pharm 2006; 3: 686-694. (Pubitemid 46087485)
24. Cummings JH, Pomare EW, Branch WJ, et al,. Short chain fatty-acids in human large-intestine, portal, hepatic and venous-blood. Gut 1987; 28: 1221-1227. (Pubitemid 17156038)
25. Sutton SC,. Role of physiological intestinal water in oral absorption. AAPS J 2009; 11: 277-285.
26. Wilding IR, Hirst PH, Connor AL,. Development of a new engineering-based capsule for human drug absorption studies. Pharm Sci Technol Today 2000; 3: 385-392.
27. Connor A, Evans P, Doto J, et al,. An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat. J Clin Pharmacol 2009; 49: 606-612.
28. Menon R, Cefali E, Wilding I, et al,. The assessment of human regional drug absorption of free acid and sodium salt forms of acipimox, in healthy volunteers, to direct modified release formulation strategy. Biopharm Drug Dispos 2009; 30: 508-516.
29. Stockis A, Sargentini-Maier ML, Otoul C, et al,. Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers. Clin Ther 2010; 32: 1813-1821.
30. Almeida AM, Castel-Branco MM, Falcão AC,. Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 774: 215-222. (Pubitemid 34655493)
31. Yang JS, Jamei M, Yeo KR, et al,. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 2007; 8: 676-684. (Pubitemid 47578116)
32. Bradford B, Rubino C, Porter S, Forrest A, Blatt L, Patat A,. A phase 1 study of the safety, tolerability, and pharmacokinetics of single ascending oral doses of the NS3/4A protease inhibitor ITMN-191 in healthy subjects. In 59th Annual Meeting of the American Association for the Study of Liver Diseases October 31-November 4, 2008 San Francisco, USA.
33. Jones HM, Parrott N, Jorga K, et al,. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 2006; 45: 511-542.
34. Peters SA, Hultin L,. Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat. J Pharmacokinet Pharmacodynam 2008; 35: 1-30. (Pubitemid 351420761)